Inflammatory bowel disease (IBD) refers to chronic inflammation conditions of the gastrointestinal tract which includes ulcerative colitis and Crohn's disease. The conditions are characterized by abdominal pain, severe diarrhea, rectal bleeding and weight loss. The current treatment options for IBD include aminosalicylates, corticosteroids, immunomodulators and biologic medications which help in effectively managing the symptoms, inducing remission and maintaining quality of life.

The global inflammatory bowel disease market is estimated to be valued at US$ 2,309.43 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The key market opportunity driving the growth of the inflammatory bowel disease market is the rising demand for treatment options across the globe. IBD prevalence is increasing worldwide and as per estimates, around 3 million people in the United States and 2.5 million people in Europe suffer from IBD. The recent surge is attributed to industrialization, urbanization and changing lifestyle patterns. The disease not only causes pain and discomfort but also psychological distress. The availability of newer targeted treatments have provided improved management of the chronic conditions. Additionally, greater awareness about IBD management among patients has also increased the demand. The market players are hence focusing on developing novel biologics and small molecules to meet the rising needs and maintain leadership in the market.

Porter’s Analysis

Threat of new entrants: The Global Inflammatory Bowel Disease Market Size has moderate threat of new entrants due to established presence of major players and requirement of high R&D investment and regulatory approvals.

Bargaining power of buyers: Buyers have moderate bargaining power due to availability of alternative treatment options and branded and generic drugs.

Bargaining power of suppliers: Suppliers have low to moderate bargaining power as raw material suppliers have availability of substitutes.

Threat of new substitutes: Threat of new substitutes is low due to no major substitute available for IBD treatment currently.

Competitive rivalry: The competitive rivalry is high due to presence of many regional and international players.

SWOT Analysis

Strength: Availability of wide range of drugs for IBD treatment. Increasing awareness about IBD symptoms and management.

Weakness: High cost of biologics. Risk of side effects associated with long term use of IBD drugs.

Opportunity: Emerging biologics and biosimilars present large market potential. Untapped opportunities in developing regions.

Threats: Patent expiries of blockbuster drugs. Generic competition eroding brand values.

Key Takeaways

The global Inflammatory Bowel Disease market is expected to witness high growth during the forecast period of 2024 to 2031. The global inflammatory bowel disease market is estimated to be valued at US$ 2,309.43 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.

Regional analysis- North America region currently dominates the global IBD market and is expected to maintain its lead during the forecast period. This is attributed to factors such as rise in IBD prevalence, favorable reimbursement scenario, and availability of advanced healthcare facilities. Asia Pacific region is anticipated to witness fastest growth due to rising awareness, growth in healthcare expenditure, and presence of generics manufacturers in the region.

Key players- Key players operating in the Inflammatory Bowel Disease market are Pfizer Inc., Atom pharma, Perrigo Company plc, Johnson and Johnson Services, Inc., Merck KGaA, Actavis Pharma, Inc., Apotex Inc., UltiMed Inc., DS LABORATORIES, INC., Taisho Pharmaceutical Co., Ltd., NIKSAN PHARMACEUTICAL, SALVAVIDAS PHARMACEUTICAL PVT. LTD., Maruti Futuristic Pharma Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy€TMs Laboratories Ltd., Lupin, Steris Healthcare PVT Ltd, Salvus Pharma, Unison Pharmaceuticals Pvt Ltd , Par Pharmaceutical, and QndQ Derma. Key players are focusing on product innovation and expansion in emerging markets for revenue growth.

Get More Insights On This Topic: https://www.ukwebwire.com/inflammatory-bowel-disease-market-forecast-outlook-trend-2023-2030/